Ares Comml Real Est (NYSE:ACRE) has received mixed analyst ratings, with a notable negative shift in sentiment. The average 12-month price target was lowered by 22.84% to $7.6. Analysts from JP Morgan, UBS, B of A Securities, and Keefe, Bruyette & Woods have all lowered their price targets, reflecting concerns over ACRE's financial health, including a significant revenue decline of -45.55%, a net margin of -238.04%, and below-average ROE and ROA.